# GLP-1s and Epilepsy Risk

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1s-and-epilepsy-risk

> People on GLP-1 drugs developed epilepsy less often than those on a different diabetes drug (hazard ratio 0.84). But the association was strongest at one year and weaker at five, which is backwards for neuroprotection.

## Key points

- Epilepsy HR 0.84 against DPP-4 inhibitors; 0.68 for semaglutide specifically.
- Strongest at 1 year (0.71), weaker at 5 (0.82), which is backwards for a neuroprotective mechanism.
- Neurology formally grades it Class III evidence, which is the journal saying it does not show cause and effect.
- The class's biggest neurologic hypothesis, Alzheimer's, has since failed two randomized trials.

A study in Neurology reports that, among people with type 2 diabetes, those on GLP-1 drugs developed epilepsy less often than those taking a different diabetes drug. The hazard ratio was **0.84**, with semaglutide strongest at 0.68.[1] The journal grades it Class III evidence, and there is a pattern inside the numbers that points away from the neuroprotection explanation.

## What was found

Compared with DPP-4 inhibitor users, GLP-1 users had a lower risk of developing epilepsy, and the association held at every follow-up point examined.[1]

*Epilepsy risk on GLP-1 drugs against DPP-4 inhibitors, by follow-up duration.*

| Follow-up | Hazard ratio |
| --- | --- |
| Overall | 0.84 (95% CI 0.78–0.90) |
| 1 year | 0.71 (95% CI 0.62–0.80) |
| 3 years | 0.81 (95% CI 0.74–0.88) |
| 5 years | 0.82 (95% CI 0.76–0.88) |
| Semaglutide specifically | 0.68 (95% CI 0.60–0.77) |

Results held across age and sex subgroups, and a sensitivity analysis excluding patients with overlapping or switching exposure returned a similar figure at 0.71.[1] The comparator is an active one, which is the design property that separates a credible observational result from a misleading one. It is the same reason we treated [the pneumonia study](https://glpwatchdog.org/research/glp1-pneumonia-and-sepsis-risk) more seriously than the cancer cohorts.

## The pattern that points the other way

Read the follow-up column downward. The association is *strongest at one year* and weaker at three and five.

> A drug that protects neurons should look better with time, not worse. This looks better early.

That shape is hard to reconcile with the neurologic-benefit hypothesis the authors raise. Protection that works through brain physiology would be expected to accumulate over years of exposure. An effect concentrated in the first year fits other explanations more comfortably: differences in who is prescribed a newer drug, in how closely those patients are watched, or in what else was happening around the time of prescribing.

None of that makes the finding wrong. It means the proposed mechanism does not match the shape of the data, and that should be noticed before anyone builds a story on top of it.

## Class III evidence, stated by the journal

Neurology formally classifies the strength of evidence in its papers, and this one is graded **Class III**.[1] That is the journal itself saying this is observational evidence with recognized limitations, not a demonstration of cause and effect. The authors also name residual confounding as a limitation directly.

> **A study that comes with its own grade is easier to use.** Most observational papers leave the reader to work out how much weight a finding carries. A formal evidence class printed on the paper is a small piece of candor, and it makes this result easier to use responsibly than dozens of louder ones.

This study asks whether these drugs change your chance of *developing* epilepsy. A different study asks what happens to *seizure recurrence* in people who already have it, and runs into the same interpretive problem from the other direction (see [seizures when you already have epilepsy](https://glpwatchdog.org/research/seizures-when-you-already-have-epilepsy)).

## What it means practically

- **It is not a reason to take a GLP-1.** No GLP-1 is approved for anything neurological, and epilepsy is uncommon enough that a relative reduction is a very small absolute one.
- **If you already have epilepsy, it is at most weakly reassuring.** The data point away from harm, not toward it, but they come from people developing epilepsy.
- **It says nothing about seizure control in existing epilepsy.** The outcome was developing epilepsy, not managing it.
- **It joins a broader pattern of proposed neurologic benefits**, one of which has now been tested directly and failed: see [the Alzheimer’s trials](https://glpwatchdog.org/research/semaglutide-alzheimers-evoke-result).

That last point deserves weight. The strongest observational signals in this class have repeatedly not survived randomization. Epilepsy has not been tested, and until it is, this belongs in the interesting column rather than the established one.

## Frequently asked questions

### Do GLP-1 drugs reduce epilepsy risk?

A study in Neurology found that, among people with type 2 diabetes, those on GLP-1 drugs developed epilepsy less often than those taking DPP-4 inhibitors, with a hazard ratio of 0.84, and 0.68 for semaglutide specifically. The journal grades it Class III evidence, meaning observational with recognized limitations.

### Why does the timing pattern matter?

Because the association was strongest at one year and weaker at three and five. A drug protecting neurons should look better with longer exposure, not worse. An effect concentrated early fits differences in prescribing or monitoring more comfortably than it fits neuroprotection.

### Should I take one for brain health?

No. Nothing in this class is approved for any neurological indication, and the most prominent neurologic hypothesis in this field, that semaglutide might slow Alzheimer's, was tested in two randomized trials that found nothing.

### I already have epilepsy. Can I safely take a GLP-1?

That is a question for your neurologist, and this study does not answer it. The outcome measured was developing epilepsy, not seizure control in people who already have it. The direction of the data is at least not suggestive of harm.

### How big is the effect in real terms?

Small. Epilepsy is an uncommon outcome, so a relative reduction of this size corresponds to a very small absolute difference: a few cases across a large population rather than anything an individual would notice.

## References

1. Cheng CY, Lo SC, Huang CN, et al. Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes. Neurology. 2026. PMID: 41370744. https://pubmed.ncbi.nlm.nih.gov/41370744/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s and Epilepsy Risk", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/glp1s-and-epilepsy-risk

Canonical HTML page: https://glpwatchdog.org/research/glp1s-and-epilepsy-risk

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
